- Home
- JHX vs SNN Comparison
JHX vs SNN Comparison
Compare JHX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHX
- SNN
- Stock Information
- Founded
- JHX 1888
- SNN 1856
- Country
- JHX Ireland
- SNN United Kingdom
- Employees
- JHX N/A
- SNN N/A
- Industry
- JHX Building Materials
- SNN Industrial Specialties
- Sector
- JHX Industrials
- SNN Health Care
- Exchange
- JHX Nasdaq
- SNN Nasdaq
- Market Cap
- JHX 13.6B
- SNN 12.3B
- IPO Year
- JHX N/A
- SNN 1999
- Fundamental
- Price
- JHX $23.58
- SNN $28.20
- Analyst Decision
- JHX Buy
- SNN Hold
- Analyst Count
- JHX 5
- SNN 3
- Target Price
- JHX $45.00
- SNN $27.00
- AVG Volume (30 Days)
- JHX 1.8M
- SNN 764.6K
- Earning Date
- JHX 05-19-2025
- SNN 02-25-2025
- Dividend Yield
- JHX N/A
- SNN 2.67%
- EPS Growth
- JHX N/A
- SNN 56.15
- EPS
- JHX 1.01
- SNN 0.47
- Revenue
- JHX $3,910,900,000.00
- SNN $5,810,000,000.00
- Revenue This Year
- JHX N/A
- SNN $6.42
- Revenue Next Year
- JHX $6.75
- SNN $5.03
- P/E Ratio
- JHX $24.01
- SNN $29.40
- Revenue Growth
- JHX 1.60
- SNN 4.70
- 52 Week Low
- JHX $23.23
- SNN $23.65
- 52 Week High
- JHX $43.57
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- JHX 24.32
- SNN 48.82
- Support Level
- JHX $23.23
- SNN $27.83
- Resistance Level
- JHX $24.78
- SNN $28.71
- Average True Range (ATR)
- JHX 0.85
- SNN 0.43
- MACD
- JHX -0.71
- SNN -0.21
- Stochastic Oscillator
- JHX 3.54
- SNN 10.14
About JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.